PL2839836T5 - Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego - Google Patents

Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego

Info

Publication number
PL2839836T5
PL2839836T5 PL14186663.2T PL14186663T PL2839836T5 PL 2839836 T5 PL2839836 T5 PL 2839836T5 PL 14186663 T PL14186663 T PL 14186663T PL 2839836 T5 PL2839836 T5 PL 2839836T5
Authority
PL
Poland
Prior art keywords
probiotics
respiratory disease
reducing symptoms
symptoms
reducing
Prior art date
Application number
PL14186663.2T
Other languages
English (en)
Polish (pl)
Other versions
PL2839836T3 (pl
Inventor
Gregory Leyer
Arthur Ouwehand
Original Assignee
International N&H Denmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2839836(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International N&H Denmark Aps filed Critical International N&H Denmark Aps
Publication of PL2839836T3 publication Critical patent/PL2839836T3/pl
Publication of PL2839836T5 publication Critical patent/PL2839836T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL14186663.2T 2006-10-02 2007-09-14 Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego PL2839836T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
EP14186663.2A EP2839836B2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing symptoms of respiratory disease
EP07838266.0A EP2068899B1 (en) 2006-10-02 2007-09-14 Lactobacillus acidophilus for use in reducing the incidence and duration of respiratory infections

Publications (2)

Publication Number Publication Date
PL2839836T3 PL2839836T3 (pl) 2018-02-28
PL2839836T5 true PL2839836T5 (pl) 2025-11-17

Family

ID=39268947

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14186663.2T PL2839836T5 (pl) 2006-10-02 2007-09-14 Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
PL07838266T PL2068899T3 (pl) 2006-10-02 2007-09-14 Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07838266T PL2068899T3 (pl) 2006-10-02 2007-09-14 Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2839836T4 (enExample)
ES (2) ES2547480T3 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2839836T5 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509151B1 (en) 2009-12-02 2014-08-20 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
KR101806435B1 (ko) 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
WO2015071389A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
AU2016227595B2 (en) 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
AU5113798A (en) * 1996-11-29 1998-06-22 Bio K & International Inc. Lactic ferment comprising a particular strain of (lactobacillus acidophilus) and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
MXPA05003597A (es) 2002-10-11 2005-06-03 Wyeth Corp Formulaciones nutricionales que contienen sustancias simbioticas.
RU2407784C2 (ru) * 2003-12-17 2010-12-27 Н.В. Нютрисиа Пробиотический штамм lactobacillus casei, продуцирующий молочную кислоту, применение штамма для приготовления питательной композиции для лечения или профилактики легочной дисфункции, питательная композиция и способ ее получения, лекарственное средство для лечения или профилактики хронической обструктивной болезни легких у субъекта и применение штамма для приготовления лекарственного средства, контейнер
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
US7981412B2 (en) * 2005-02-15 2011-07-19 Gorbach Sherwood L Food containing a probiotic and an isolated β-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
EP1951273B1 (en) 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Also Published As

Publication number Publication date
US20140356329A1 (en) 2014-12-04
EP2839836B1 (en) 2017-08-30
ES2547480T3 (es) 2015-10-06
EP2839836B2 (en) 2024-06-26
MX2009003260A (es) 2009-05-11
CN101528244B (zh) 2012-01-11
CN101528244A (zh) 2009-09-09
KR20140002069A (ko) 2014-01-07
ES2650375T3 (es) 2018-01-18
US20200316145A1 (en) 2020-10-08
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
US20180000875A1 (en) 2018-01-04
JP2014058558A (ja) 2014-04-03
KR20090063222A (ko) 2009-06-17
PL2068899T3 (pl) 2015-12-31
KR101474188B1 (ko) 2014-12-17
EP2068899A2 (en) 2009-06-17
DK2839836T3 (en) 2017-12-04
KR101485200B1 (ko) 2015-01-26
EP2839836A1 (en) 2015-02-25
US20100040579A1 (en) 2010-02-18
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
AU2007302715A1 (en) 2008-04-10
JP2010505824A (ja) 2010-02-25
WO2008042101A3 (en) 2009-04-09
EP2068899B1 (en) 2015-07-01
AU2007302715B2 (en) 2013-01-31
FI2839836T4 (fi) 2024-08-26
DK2839836T4 (da) 2024-08-26
PL2839836T3 (pl) 2018-02-28
US20230256037A1 (en) 2023-08-17
DK2068899T3 (da) 2015-09-28
ES2650375T5 (en) 2025-02-03

Similar Documents

Publication Publication Date Title
PL2839836T5 (pl) Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
PT2077729E (pt) Formas orais probióticas
GB0625659D0 (en) Therapeutic compounds and their use
EP2094154A4 (en) BREATHING THE FLIGHT OF HORSES
ZA200903262B (en) Ventilator for rapid response to respiratory disease conditions
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
IL195247A0 (en) Inhaler
PL2007457T3 (pl) Inhalator
IL193693A0 (en) Purine compounds and methods of use thereof
IL182407A0 (en) Use of agomelating in obtaining medicaments intended for the treatment of generalized anxiety disorder
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
GB2434754B (en) Inhaler
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
PL2068901T3 (pl) Zastosowanie hydroksytyrozolu do zmniejszenia ilości kwasu mlekowego w osoczu
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
GB2436290B (en) Patient calming arrangements
GB0607402D0 (en) Therapeutic composition and use
GB0701456D0 (en) Treatment for respiratory disease
AP2006000208S (en) Inhaler
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
EP1963768A4 (en) EVAPORATOR AND THE SAME METHOD
ZA200807956B (en) Purine compounds and methods of use thereof
GB0623740D0 (en) Treatment of disease